TV News LIES

Saturday, Aug 27th

Last update05:20:13 AM GMT

You are here News Health Study outcome won't sway company on eye drug

Study outcome won't sway company on eye drug

E-mail Print PDF

What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?

In the case of Genentech Inc., nothing.

The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance _ or cooperate with _ a National Eye Institute study comparing the effectiveness and safety of Avastin, a cancer drug, and the more expensive eye drug, Lucentis.

More...


Most Recent Related Stories...


EpiPen maker offers patients $300 savings cards

EpiPen discount cardMylan N.V., makers of the anti-allergic reaction EpiPen, announced programs Thursday to lower the device's cost...

Dem senator's daughter could face Congress over EpiPen price hike

Epipen price hikeSen. Joe Manchin's (D-W.Va.) daughter may have to explain to Congress why her company hiked up...

Monsanto pulls new GM cotton seed from India in protest

Monsanto pulls GM seed from IndiaMonsanto Co (MON.N) has withdrawn an application seeking approval for its next generation of genetically modified...

Toxic Firefighting Foams Won’t Be Used In Air Force Bases Anymore

Toxic firefighting foam will not be usedA toxic firefighting foam that may have tainted drinking water near military sites with cancer-causing chemicals...
 
America's # 1 Enemy
Tee Shirt
& Help Support TvNewsLIES.org!
TVNL Tee Shirt
 
TVNL TOTE BAG
Conserve our Planet
& Help Support TvNewsLIES.org!
 
Get your 9/11 & Media
Deception Dollars
& Help Support TvNewsLIES.org!
 
The Loaded Deck
The First & the Best!
The Media & Bush Admin Exposed!